World-First 760 kDa Long-Acting Botulinum Technology
OBI-858 is a novel botulinum toxin type A therapeutic developed by Obigen Pharma, featuring a unique 760 kDa toxin protein structure designed to deliver rapid onset, prolonged duration, and a strong safety profile.
Advantages
- Visible results in as little as 2-3 days.
- Clinical efficacy lasting up to approximately 6 months.
- One of the few long-acting botulinum toxin development platforms worldwide.
- Strong potential for expansion across both aesthetic and therapeutic indications.
- Halal-certified, supporting broader global market opportunities.
Brand Positioning
Faster Results. Longer Lasting. Setting a New Standard in Botulinum Toxin Therapy.
Integrated Development & Manufacturing Excellence
From strain research, process development, CMC, manufacturing, and clinical validation, Obigen Pharma has established an integrated in-house development platform that enhances operational efficiency, strengthens quality control, and supports successful commercialization.
Mechanism of Action
OBI-858 works by inhibiting the release of acetylcholine at nerve terminals, temporarily reducing muscle activity and helping improve dynamic wrinkles as well as selected neuromuscular conditions.